IDEAYA Biosciences (IDYA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $32.85, -2.95% vs the prior close of $33.85.
- Volume 655.11K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IDYA dips 3.0% to $32.85, a 3-month low, 5 down days in a row. Closed at $32.85, -2.95% vs the prior close of $33.85. Day range $32.72–$33.97, opened at $33.97.
IDYA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — IDYA dips 3.0% to $32.85, a 3-month low, 5 down days in a row
- Closed at $32.85, -2.95% vs the prior close of $33.85. Day range $32.72–$33.97, opened at $33.97.
- Volume was 655.11K shares, 0.8x its 50-day average of 785.80K.
- Price is -13.3% vs its 50-day average ($37.89) and -3.7% vs its 200-day average ($34.12).
- 52-week range $26.81–$42.68; today's close sits at 38% of that range, 23.0% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — IDYA ends flat (-0.0%) to $33.85, a 3-month low, 4 down days in a row
- Closed at $33.85, -0.03% vs the prior close of $33.86. Day range $33.62–$34.67, opened at $34.24.
- Volume was 1.34M shares, 1.7x its 50-day average of 779.06K.
- Price is -10.8% vs its 50-day average ($37.96) and -0.8% vs its 200-day average ($34.12).
- 52-week range $26.81–$42.68; today's close sits at 44% of that range, 20.7% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — IDYA dips 1.2% to $33.86, a 3-month low, 3 down days in a row
- Closed at $33.86, -1.17% vs the prior close of $34.26. Day range $33.62–$34.84, opened at $34.38.
- Volume was 1.06M shares, 1.4x its 50-day average of 782.87K.
- Price is -10.9% vs its 50-day average ($38.00) and -0.8% vs its 200-day average ($34.13).
- 52-week range $26.44–$42.68; today's close sits at 46% of that range, 20.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — IDYA slides 5.0% to $34.26, a 3-month low
- Closed at $34.26, -4.99% vs the prior close of $36.06. Day range $34.25–$36.20, opened at $36.06.
- Volume was 1.03M shares, 1.3x its 50-day average of 770.28K.
- Price is -10.0% vs its 50-day average ($38.05) and +0.4% vs its 200-day average ($34.14).
- 52-week range $26.20–$42.68; today's close sits at 49% of that range, 19.7% below the 52-week high.
Oct 12, 2026 — IDYA ends flat (-0.1%) to $36.06
- Closed at $36.06, -0.14% vs the prior close of $36.11. Day range $35.66–$36.42, opened at $35.98.
- Volume was 441.50K shares, 0.6x its 50-day average of 771.09K — lighter than usual.
- Price is -5.3% vs its 50-day average ($38.07) and +5.6% vs its 200-day average ($34.14).
- 52-week range $26.05–$42.68; today's close sits at 60% of that range, 15.5% below the 52-week high.
Oct 9, 2026 — IDYA ends flat (+0.1%) to $36.11
- Closed at $36.11, +0.14% vs the prior close of $36.06. Day range $35.94–$36.72, opened at $35.94.
- Volume was 698.90K shares, 0.9x its 50-day average of 771.93K.
- Price is -5.1% vs its 50-day average ($38.06) and +5.8% vs its 200-day average ($34.14).
- 52-week range $26.05–$42.68; today's close sits at 60% of that range, 15.4% below the 52-week high.
Oct 8, 2026 — IDYA dips 0.6% to $36.06, a 1-month low, 3 down days in a row
- Closed at $36.06, -0.55% vs the prior close of $36.26. Day range $35.10–$36.32, opened at $35.85.
- Volume was 548.70K shares, 0.7x its 50-day average of 780.81K.
- Price is -5.3% vs its 50-day average ($38.06) and +5.6% vs its 200-day average ($34.14).
- 52-week range $26.05–$42.68; today's close sits at 60% of that range, 15.5% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — IDYA dips 1.0% to $36.26, a 1-month low
- Closed at $36.26, -1.01% vs the prior close of $36.63. Day range $36.00–$36.97, opened at $36.19.
- Volume was 552.10K shares, 0.7x its 50-day average of 782.87K.
- Price is -4.7% vs its 50-day average ($38.05) and +6.3% vs its 200-day average ($34.12).
- 52-week range $26.05–$42.68; today's close sits at 61% of that range, 15.0% below the 52-week high.
Oct 6, 2026 — IDYA slides 3.8% to $36.63, a 1-month low
- Closed at $36.63, -3.76% vs the prior close of $38.06. Day range $36.11–$38.56, opened at $38.23.
- Volume was 802.50K shares, 1.0x its 50-day average of 790.28K.
- Price is -3.7% vs its 50-day average ($38.05) and +7.4% vs its 200-day average ($34.11).
- 52-week range $26.05–$42.68; today's close sits at 64% of that range, 14.2% below the 52-week high.
Oct 5, 2026 — IDYA rises 1.9% to $38.06
- Closed at $38.06, +1.87% vs the prior close of $37.36. Day range $37.04–$38.26, opened at $37.57.
- Volume was 658.00K shares, 0.8x its 50-day average of 795.15K.
- Price is +0.0% vs its 50-day average ($38.06) and +11.6% vs its 200-day average ($34.09).
- 52-week range $26.05–$42.68; today's close sits at 72% of that range, 10.8% below the 52-week high.
Oct 2, 2026 — IDYA dips 1.2% to $37.36
- Closed at $37.36, -1.19% vs the prior close of $37.81. Day range $37.00–$38.54, opened at $38.52.
- Volume was 579.00K shares, 0.7x its 50-day average of 800.53K.
- Price is -1.7% vs its 50-day average ($38.00) and +9.6% vs its 200-day average ($34.07).
- 52-week range $26.05–$42.68; today's close sits at 68% of that range, 12.5% below the 52-week high.
IDYA latest news & SEC filings
Every SEC filing by or about IDYA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hata Yujiro S converted options/RSUs into 26,338 shares at $4.31 (≈$113.52K) on Oct 6, 2026; now holds 717,033
- Hata Yujiro S sold 25,538 shares at $37.39 (≈$954.79K) on Oct 6, 2026; now holds 691,495
- Hata Yujiro S sold 800 shares at $38.26 (≈$30.61K) on Oct 6, 2026; now holds 690,695
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $8.86M
- Net income: -$112.45M (prior year -$77.49M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.22 (prior year -$0.88) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ruiz Briseno Andres sold 9,550 shares at $40.01 (≈$382.10K) on Jul 7, 2026
- Ruiz Briseno Andres sold 9,550 shares at $40.01 (≈$382.10K) on Jul 7, 2026
- Ruiz Briseno Andres sold 9,550 shares at $40.01 (≈$382.10K) on Jul 7, 2026
- Ruiz Briseno Andres sold 9,550 shares at $40.01 (≈$382.10K) on Jul 7, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 7, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade IDYA
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 17, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.85% (largest 5.7%).
- Liquidity: about 863.83K shares (≈$28.38M) trade per day on average.
- 52-week position: $32.85 vs a range of $26.81–$42.68 (38% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 4 sales; latest: Briseno Andres Ruiz sold 9,550 shares on Jul 7, 2026.
- Latest filings: 10-Q Aug 4, 2026; 8-K Aug 4, 2026; 8-K Jun 23, 2026.
- Share count: 96.49M shares outstanding (Jul 31, 2026), +10.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
IDYA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 33.97 | 33.97 | 32.72 | 32.85 | 655.11K |
| Oct 15, 2026 | 34.24 | 34.67 | 33.62 | 33.85 | 1.34M |
| Oct 14, 2026 | 34.38 | 34.84 | 33.62 | 33.86 | 1.06M |
| Oct 13, 2026 | 36.06 | 36.20 | 34.25 | 34.26 | 1.03M |
| Oct 12, 2026 | 35.98 | 36.42 | 35.66 | 36.06 | 441.50K |
| Oct 9, 2026 | 35.94 | 36.72 | 35.94 | 36.11 | 698.90K |
| Oct 8, 2026 | 35.85 | 36.32 | 35.10 | 36.06 | 548.70K |
| Oct 7, 2026 | 36.19 | 36.97 | 36.00 | 36.26 | 552.10K |
| Oct 6, 2026 | 38.23 | 38.56 | 36.11 | 36.63 | 802.50K |
| Oct 5, 2026 | 37.57 | 38.26 | 37.04 | 38.06 | 658.00K |
| Oct 2, 2026 | 38.52 | 38.54 | 37.00 | 37.36 | 579.00K |
| Oct 1, 2026 | 38.34 | 39.32 | 37.62 | 37.81 | 712.30K |
| Sep 30, 2026 | 38.11 | 39.39 | 37.76 | 38.42 | 1.02M |
| Sep 29, 2026 | 38.14 | 38.42 | 37.20 | 37.86 | 815.40K |
| Sep 28, 2026 | 36.26 | 38.73 | 36.10 | 38.22 | 1.05M |
| Sep 25, 2026 | 36.74 | 36.99 | 36.16 | 36.69 | 487.30K |
| Sep 24, 2026 | 37.46 | 37.78 | 35.59 | 36.74 | 1.27M |
| Sep 23, 2026 | 39.74 | 39.88 | 37.00 | 37.46 | 2.24M |
| Sep 22, 2026 | 39.11 | 40.00 | 38.93 | 39.71 | 745.80K |
| Sep 21, 2026 | 38.71 | 39.00 | 37.99 | 38.86 | 571.10K |
About IDEAYA Biosciences
IDEAYA Biosciences (IDYA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SOUTH SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1676725.
IDYA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Malcolm Garret Hampton | Director | Jun 18, 2026 |
| Yujiro S Hata | President and CEO | Feb 2, 2026 |
| Catherine J Mackey | Director | Jun 18, 2026 |
| Scott W Morrison | Director | Jun 18, 2026 |
| Terry J Rosen | Director | Jun 18, 2026 |
| Jeffrey Stein | Director | Jun 18, 2026 |
| Wendy L Yarno | Director | Jun 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Darrin Beaupre | Chief Medical Officer | Feb 2, 2026 |
| Joshua Bleharski | Chief Financial Officer | Feb 2, 2026 |
| Stuart Dorman | Chief Commercial Officer | Feb 2, 2026 |
| Yujiro S Hata | President and CEO | Feb 2, 2026 |
| Theodora Ross | Chief Development Officer | Jun 5, 2026 |
| Briseno Andres Ruiz | Chief Accounting Officer | Jul 9, 2026 |
| Douglas B. Snyder | SVP, General Counsel | Feb 2, 2026 |
| Michael Anthony White | Chief Scientific Officer | Feb 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 7, 2026 | Briseno Andres Ruiz | Sale | 9,550 | $40.01 |
| Jul 7, 2026 | Briseno Andres Ruiz | Sale | 9,550 | $40.01 |
| Jul 7, 2026 | Briseno Andres Ruiz | Sale | 9,550 | $40.01 |
| Jul 7, 2026 | Briseno Andres Ruiz | Sale | 9,550 | $40.01 |
| Mar 2, 2026 | Jeffrey Stein | Buy | 50,000 | $32.96 |
| Mar 2, 2026 | Jeffrey Stein | Buy | 50,000 | $32.96 |
| Mar 2, 2026 | Jeffrey Stein | Buy | 50,000 | $32.96 |
| Mar 2, 2026 | Jeffrey Stein | Buy | 50,000 | $32.96 |
IDYA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $218.71M | $-113.70M | -1.28 | $-71.10M |
| Dec 31, 2024 | $7.00M | $-274.48M | -3.36 | $-247.58M |
| Dec 31, 2023 | $23.39M | $-112.96M | -1.96 | $-115.22M |
| Dec 31, 2022 | $50.93M | $-58.66M | -1.42 | $-87.17M |
| Dec 31, 2021 | $27.94M | $-49.76M | -1.41 | $-55.78M |
Latest balance sheet: total assets $1.31B, total liabilities $110.79M, cash $272.59M (as of Jun 30, 2026).
IDYA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $36.11 |
| May 5, 2026 | 8-K Item 2.02 (results) | $28.80 |
| Feb 17, 2026 | 8-K Item 2.02 (results) | $30.76 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $30.48 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $24.12 |
| May 6, 2025 | 8-K Item 2.02 (results) | $17.75 |
| Feb 13, 2025 | 8-K Item 2.02 (results) | $20.76 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $30.00 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| Jul 9, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 20, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on IDYA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.